The association between DPP-4 inhibitors and pancreatic cancer remains inconclusive in global studies [27], and this uncertainty extends to Japanese populations as large Japanese cohort studies have not demonstrated a statistically significant increase in pancreatic cancer risk with DPP-4 inhibitors [29]. Here, DPP4 is linked to familial pancreatic carcinoma.